The heparin recall of 2008

Perfusion (United Kingdom)

Volumn 28, Issue 1, 2013, Pages 61-65

  Hedlund, K D ^a   Coyne, D P ^b   Sanford, D M ^c   Huddelson, J ^d  

^a Hays Medical Center   (United States)

^b Kansas Medical Center   (United States)

^c Jefferson Regional Medical Center   (United States)

^d Self Regional Hospital   (United States)

Author keywords

anticoagulant; antithrombin III; cardiopulmonary bypass; Heparin; heparin contamination

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BRADYKININ; CHONDROITIN SULFATE; DERMATAN SULFATE; FONDAPARINUX; HEPARIN; IDURONIC ACID;

ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; CAUSE OF DEATH; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; DEATH; DIALYSIS; DRUG INDUSTRY; DRUG POTENCY; DYSPNEA; FEVER; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPOTENSION; KALLIKREIN KININ SYSTEM; NAUSEA; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; SHOCK; STRIDOR; SULFONATION; SWELLING; TACHYCARDIA;

CHINA; CHONDROITIN SULFATES; DRUG CONTAMINATION; DRUG RECALLS; HEPARIN; HUMANS;

EID: 84871551863     PISSN: 02676591     EISSN: 1477111X     Source Type: Journal    
DOI: 10.1177/0267659112462274     Document Type: Article

References (20)

1. Bigelow WG Mysterious heparin: the key to open heart surgery. Toronto: McGraw-Hill Ryerson ; 1990 :
2. Despotis GJ, Joist JH. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update. J Cardiothorac Vasc Anesth. 1999 ; 13: 18-29
3. Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature. 2007 ; 446: 1030-1037
4. Howell WH, Holt B. Two new factors in blood coagulation-heparin and pro-antithrombin. Amer J Physiol. 1918 ; 47: 328-341
5. Best CH. Preparation of heparin and its use in the first clinical case. Circulation. 1959 ; 19: 79-86
6. QuinnK. St. Louis hospitals help uncover batches of contaminated heparin. www.ksdk.com04/30/2008.
7. Baxter Healthcare Corporation Urgent Product RecallJanuary17, 2008.
8. MetzgerLC. The scoop on heparin. www.oley.org04/10/2008.
9. PowellB. Heparin's deadly side effects. www.time.com11/13/2008.
10. HarrisG. Problems in blood drug lead to halt by factory. www.nytimes.com02/12/2008.
11. Kishimoto TK, Viswanathan K, Ganguly T, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med. 2008 ; 358: 2457-2467
12. Guerrini M, Beccati D, Shriver Z, et al. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nature Biotechnol. 2008 ; 26 (6). 669-675
13. Beni S, Limtiaco JFK, Larive CK. Analysis and characterization of heparin impurities. Anal Bioanal Chem. 2011 ; 399: 527-539
14. Liu H, Zhang Z, Linhardt RJ. Lessons learned from the contamination of heparin. Nat Prod Rep. 2009 ; 26: 313-321
15. Maruyama T, Toida T, Imanari T, et al. Conformational changes and anticoagulant activity of chondroitin sulfate following O-sulfonation. Carbohydr Res. 1998 ; 306: 35-43
16. RoyceK. FDA failures contribute to spread of contaminated drugs. www.worldfocus.org12/17/2008.
17. Heparin potency unit assignment and harmonization with the international standard for unfractionated heparin. Release date. 2009 ;:
18. Barrowcliffe TW. History of heparin. Handb Exp Pharmacol. 2012 ; 207: 3-22
19. Petitou M, van Boeckel CA. A synthetic antithrombin III binding pentasaccharide is now a drug: what comes next?. Angew Chem Int Ed. 2004 ; 43: 3118-3133
20. Turnbull JE. Getting the farm out of pharma for heparin production. Science. 2011 ; 334: 462-463